Chadi Abdallah
Associate Professor Adjunct of Psychiatry; Deputy Director for Research and Director of Neuroimaging, Clinical Neuroscience Division, VA National Center for PTSD
Data updated
Research Footprint
Chadi Abdallah appears in 12 tracked papers (2014–2022), most studied alongside Ketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and PTSD.
Most-cited paper: Targeting glutamate signalling in depression: progress and prospects (478 citations).
Frequent co-authors: John Krystal, Lauren Averill and Gerard Sanacora.
Background & Research
Dr. Chadi G. Abdallah is a psychiatrist and translational clinical neuroscientist focused on antidepressant clinical trials, multimodal neuroimaging, and mechanisms of rapid-acting antidepressants. His research examines depression, PTSD, and other stress-related disorders, with emphasis on synaptic connectivity, neuroenergetics, and treatment response. He has held faculty appointments at Yale and is currently affiliated with Baylor College of Medicine and the VA National Center for PTSD.
Key Impact
A leading ketamine and rapid-acting antidepressant researcher whose work has helped define the neurobiology, biomarkers, and clinical use of ketamine in depression and PTSD.
Collaboration Network
24 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Chadi Abdallah is associated with.
Baylor College of Medicine
Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →